{"filings":[{"id":748684,"accession_number":"0001193125-26-248640","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2026-05-29T21:00:16+00:00","items":["2.03","9.01"],"status":"ready","headline":"TuHURA Biosciences draws $1.7M from $50M revolving credit facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["First draw of $1.7M under $50M revolving credit facility with Parkview Holdings One LLC.","Facility matures April 21, 2031; proceeds for general corporate purposes.","Loan Agreement terms unchanged; full agreement filed on April 22, 2026.","Ticker: HURA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":472876,"accession_number":"0001193125-26-227204","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2026-05-15T21:10:20+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"TuHURA Q1 cash $6.3M; secures $50M credit facility; IFx-2.0 gets ODD in melanoma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and equivalents $6.3M at March 31, 2026; net operating cash outflow $4.4M in Q1.","Established $50M credit facility with largest stockholder at 12% interest, maturing 2031; extends runway into 2028.","R&D expenses $5.2M (up from $4.6M YoY); G&A $2.3M (up from $2.0M YoY).","FDA Orphan Drug Designation granted for IFx-2.0 in stage IIB-IV melanoma.","Appointed Craig Tendler as CMO and Amanda Garofalo as SVP Clinical Operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93208,"accession_number":"0001193125-26-197609","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K/A","filed_at":"2026-04-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"TuHURA corrects pro forma financials for Kineta merger; FY2025 net loss $34.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Corrected unaudited pro forma combined net loss for FY2025: $34.5M ($34.6M attributable to common), EPS -$0.66.","Prior 8-K filed April 8, 2026 contained errors; this amendment replaces Exhibit 99.1 entirely.","Merger with Kineta closed June 30, 2025; Kineta stockholders received 3.998M shares (7.6% of combined entity).","TuHURA issued 4.76M shares + warrants in a June 2025 PIPE for net proceeds of $11.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93211,"accession_number":"0001193125-26-168395","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"TuHURA secures $50M credit facility from largest stockholder affiliate to fund operations into Q1 2028","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$50M revolving credit facility from Parkview (affiliate of largest stockholder) at 12% interest, matures April 2031.","Monthly draws capped at greater of $1.7M or monthly budget; expects runway into Q1 2028.","Commitment fee $5M paid in 1.88M shares (subject to stockholder approval) or cash; annual 1.5% facility fee.","Granted low-to-mid single digit royalty on IFx-2.0 sales up to $450M/year; warrants extended to 2031.","Change of control conversion price $2.662/share, requires stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93210,"accession_number":"0001193125-26-147660","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2026-04-08T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"TuHURA pro forma 2025 net loss $34.6M after Kineta acquisition; exec bonuses approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pro forma net loss attributable to common stockholders $34.57M, or $(0.64) per share, for year ended Dec 31, 2025.","Kineta merger closed June 30, 2025; Kineta shareholders received ~3.998M TuHURA shares (7.6% post-merger ownership).","Concurrent June 2025 private placement raised $11.5M net from 4.76M shares and warrants at $2.65/unit.","CEO Bianco awarded $490,536 bonus; new salary $605,956. CFO Dearborn awarded $163,393 bonus; new salary $403,676.","No cash consideration paid at closing due to Kineta working capital deficit of $5.255M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93209,"accession_number":"0001193125-26-135766","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TuHURA FY2025 cash $3.6M, R&D $20.5M; Phase 3 MCC trial ongoing; Kineta acquired","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $3.6M at Dec 31, 2025; additional $7.5M from 2025 registered direct offering received Q1 2026.","R&D expenses $20.5M for FY2025 vs $14.7M in FY2024; operating cash outflow $27.7M.","Phase 3 trial of IFx-2.0 in Merkel cell carcinoma initiated under FDA SPA; enrollment estimated to complete mid-2027.","Closed $10.5M acquisition of Kineta, gaining VISTA antibody TBS-2025; $21.2M raised in 2025 offerings.","Upcoming milestones: FDA meeting for TBS-2025 in June 2026; ADC lead selection in 1H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104660,"accession_number":"0001193125-26-031742","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"TuHURA receives Nasdaq delisting notice for bid price below $1.00; 180-day cure period until July 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq letter on Jan 29, 2026, for bid price <$1.00 for 35 consecutive days, violating Listing Rule 5550(a)(2).","Company has 180-day grace period, until July 28, 2026, to regain compliance by closing bid price ≥$1.00 for 10 consecutive days.","If not compliant by July 28, a second 180-day period may be available if other listing standards are met.","Company will monitor bid price and consider options, including a potential reverse stock split to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120937,"accession_number":"0001193125-25-314302","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"TuHURA Biosciences prices $15.6M registered direct offering of stock and warrants in three tranches","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TuHURA prices registered direct offering of 9.46M shares and Series A/B warrants at $1.65/unit; warrants exercisable at $1.95 after six months.","First closing $8.6M on Dec 10; second $5M by Jan 30, 2026; third $2M by Feb 27, 2026; total gross ~$15.6M.","Net proceeds for working capital and to repay $3.4M bridge note (3%/mo, due Dec 31, 2025) to Matthew Nachtrab Revocable Trust.","30-day lock-up for directors/officers; 30-day halt on equity issuance; 6-month ban on variable rate transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120936,"accession_number":"0001193125-25-309853","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"TuHURA draws additional $1.5M under amended loan; total $3M, issues warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowed an additional $1.5M on Dec 2, 2025, bringing aggregate loans to $3.0M under the Loan Agreement.","Amendment extends availability period to Dec 5, 2025 and sets warrants at 150K shares per $1.5M borrowed.","Issued warrant to purchase 234,783 shares at $1.81/share, expiring in two years.","Lender is Matthew Nachtrab Revocable Trust; warrants cover both the initial and second loan advances."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120935,"accession_number":"0001193125-25-294581","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"TuHURA Biosciences S-3 shelf registration becomes effective; resale S-1 terminated","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["S-3 registration statement (File No. 333-291239) declared effective by SEC on November 22, 2025.","Offering of up to 9,321,545 shares previously registered under S-1 is now covered by the new shelf.","Private placement completed June 2, 2025; warrants for 4,750,916 shares included in registered shares.","Prior resale S-1 (File No. 333-289532) deemed terminated as of shelf effective date.","Selling securityholders may now offer shares from time to time under the shelf registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120934,"accession_number":"0001193125-25-286419","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"TuHURA provides pro forma statements for Kineta merger, closed June 30, 2025","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Pro forma combined statements for nine months ended Sept 30, 2025 and year ended Dec 31, 2024.","Kineta acquisition accounted for as business combination; TuHURA as acquirer with 92.4% ownership post-merger.","Pro forma adjustments eliminate pre-merger intercompany transactions and financing costs.","TuHURA advancing Kineta's VISTA-101 trial; REM-001 study underway with CVR milestone by Dec 31, 2025.","Historical financials of TuHURA remain the consolidated financial statements post-merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120933,"accession_number":"0001193125-25-281522","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TuHURA reports Q3 R&D $4.9M, cash burn $22.1M; Phase 3 MCC trial underway","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Phase 3 IFx-2.0 trial for MCC under SPA enrollment ongoing; topline results expected Q1 2027.","R&D expenses $4.9M (Q3 2025) vs $2.9M (Q3 2024); 9-month net cash outflow $22.1M vs $12.1M.","DOR technology selected for oral presentation at ASH 2025 Annual Meeting in December.","Appointed Dr. Michael Turner as Vice President of Immunology in November 2025.","Filed $50M ATM facility in November 2025; not yet effective."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120932,"accession_number":"0001193125-25-263523","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"TuHURA Biosciences enters ATM agreement for up to $50M in common stock sales","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $50M of common stock may be sold through H.C. Wainwright as sales agent.","Wainwright receives 3.0% cash commission; company reimburses up to $75K in legal fees.","Proceeds will be used for working capital and general corporate purposes.","Either party may suspend or terminate the offering; no assurance any shares will be sold.","Registration statement on Form S-3 filed same day; sales begin once SEC declares effective."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120931,"accession_number":"0001193125-25-262562","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"TuHURA starts Phase 3 IFx-2.0 trial, acquires TBS-2025, defers IFx-3.0","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initiated Phase 3 trial of IFx-2.0 + Keytruda in 1L Merkel cell carcinoma under FDA SPA for accelerated approval.","Acquired VISTA-inhibiting mAb TBS-2025 via Kineta merger (June 2025); planning Phase 2 in mutNPM1 AML.","Deferred development of IFx-3.0 mRNA candidate pending IFx-2.0 Phase 3 data; resources shifted to TBS-2025.","Filed unaudited pro forma financials reflecting Kintara (Oct 2024) and Kineta (June 2025) mergers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120930,"accession_number":"0001193125-25-260924","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2025-10-31T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"TuHURA secures $3M bridge loan at 3% monthly interest, secured by ImmuneFx patents","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial $1.5M advance from Matthew Nachtrab Revocable Trust on Oct 27, 2025; up to $3M total available.","Interest at 3% per month (36% annual); $180K loan fee plus warrants covering 10% of each advance.","Loan secured by first-priority lien on U.S. patents for ImmuneFx technology platform.","Maturity Dec 31, 2025 or 30 days after an equity raise >$12M; proceeds for working capital.","Prepayment allowed without penalty; lender may fund additional $1.5M upon written request."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137522,"accession_number":"0000950170-25-114235","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"TuHURA closes $3.2M final tranche; extends 2024 warrants for 1.5M shares to 2030","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deferred investors purchased $3.2M of final tranche on Sept 5, 2025, accelerating ~80% of the remaining $3.7M offering.","Expiration of 2024 warrants covering 1.5M shares extended from original dates to December 31, 2030.","Total private placement aggregates ~$12.6M; earlier tranches of ~$8.9M were completed by July 24, 2025.","Remaining ~$0.5M must be purchased by December 31, 2025; those shares will not be registered for resale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137521,"accession_number":"0000950170-25-108909","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TuHURA Q2 R&D $4.9M, initiates Phase 3 IFx-2.0 trial, acquires Kineta VISTA mAb","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed acquisition of Kineta; VISTA mAb (TBS-2025) Phase 2 AML trial planned for 2H 2025.","Initiated Phase 3 accelerated approval trial of IFx-2.0 with Keytruda in MCC under FDA SPA.","Raised $12.5M equity financing plus $3.0M from warrant exercise in June 2025; shares outstanding ~49.9M.","R&D expenses $4.9M (Q2 2025) vs $2.8M (Q2 2024); operating cash outflow ($10.9M) for 6 months.","Added to Russell 3000/2000 indices in June 2025; targets Phase 3 topline results 2H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137520,"accession_number":"0001193125-25-178993","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K/A","filed_at":"2025-08-12T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Kineta acquisition closed; Q1 2025 financials show $1.7M net loss and $13.2M deficit","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cash $304K, total liabilities $14M, stockholders' deficit $13.2M as of March 31, 2025.","Net loss attributable to Kineta for Q1 2025 was $1.676M vs $10.238M in Q1 2024 on reduced R&D spend.","Accumulated deficit reached $184.6M; Kineta has going concern warning with insufficient cash for next 12 months.","Merger consideration includes up to $16.5M initial stock, $6.5M delayed stock, $12M cash (net of exclusivity credits and working capital adjustments)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154880,"accession_number":"0000950170-25-091693","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["2.01","7.01","9.01"],"status":"ready","headline":"TuHURA completes Kineta acquisition, adds Phase 2 VISTA mAb TBS-2025","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Each Kineta share converted into 0.185298 TuHURA shares; ~2.87M shares issued at closing, plus up to ~1.13M additional shares subject to six-month adjustment.","VISTA-inhibiting antibody renamed TBS-2025; TuHURA plans Phase 2 trial in NPM1 mutated AML in 2H 2025.","Acquisition unlocks fourth tranche of $12.5M PIPE financing announced June 3, 2025.","TuHURA believes TBS-2025 can overcome acquired resistance to cancer immunotherapy; exploring ADC synergies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154879,"accession_number":"0000950170-25-090522","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"TuHURA Biosciences increases authorized common shares from 75M to 200M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment at June 23, 2025 special meeting.","Filed Certificate of Amendment with Nevada Secretary of State on June 23, 2025.","Authorized capital now 200M common shares ($0.001 par) and 5M preferred shares ($0.001 par).","Amendment increases potential for future equity financings or stock issuances."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154878,"accession_number":"0000950170-25-089118","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"TuHURA and Kineta stockholders approve merger; authorized shares increased to 200M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["TuHURA shareholders approved all proposals: authorized shares increased from 75M to 200M, reincorporation to Delaware.","Kineta stockholders also approved the merger with TuHURA at their June 23, 2025 special meeting.","Parties expect merger to close soon after satisfaction of remaining closing conditions.","TuHURA elected six directors, approved executive compensation (non-binding), and ratified auditor Cherry Bekaert for FY2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154877,"accession_number":"0000950170-25-085116","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"TuHURA raises CEO salary to $577K, CFO to $384K; approves 2024 bonuses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO James Bianco base salary increased to $577,101; CFO Dan Dearborn to $384,453 effective June 6, 2025.","Compensation committee set salaries at ~90% of peer group median.","FY2024 bonus: Bianco $579,668, Dearborn $339,101, former CEO Hoffman $397,669.","Revised summary comp table: Bianco total $6.0M, Dearborn $2.9M.","Former CEO Hoffman received $1.3M severance after termination post-Kintara merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154876,"accession_number":"0001193125-25-137135","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"TuHURA raises $12.6M in private placement, $3M from warrants, tied to Phase 3 & merger milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total offering $12.6M (4.76M shares + warrants at $2.65/unit). Initial closing $2.23M.","$9M purchased in four tranches tied to milestones: FDA partial clinical hold lift, Phase 3 start, Kineta merger close.","Remaining $3.7M due by Dec 31, 2025. Also received $3.0M from Feb 2025 warrant exercise.","Proceeds to fund Kineta merger closing, Phase 3 trial of IFx-2.0, and advancement of KVA12123 to Phase 2.","Warrants exercisable at $3.3125, 5-year term, subject to authorized share increase."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154875,"accession_number":"0000950170-25-072685","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TuHURA Q1 expenses rise; Phase 3 MCC trial and Kineta merger on track for Q2 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q1 2025 R&D expenses $4.6M (up 28% YoY); G&A $2.4M (up 140% YoY); shares outstanding ~43.7M.","Initiated Phase 1b/2a trial of IFx-Hu2.0 plus pembrolizumab in first-line Merkel cell carcinoma of unknown primary in May 2025.","Targeting Q2 2025 close of Kineta acquisition; Phase 2 trial of VISTA mAb in NPM1-mutated AML expected Q3 2025.","Phase 3 accelerated approval trial of IFx-Hu2.0 in advanced Merkel cell carcinoma expected to start Q2 2025 after lifting partial clinical hold.","Appointed Dr. Bertrand Le Bourdonnec as EVP Head of Drug Discovery in April 2025; Dr. Craig Tendler joined Board in March 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154874,"accession_number":"0000950170-25-065057","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"TuHURA amends Kineta merger; revises consideration, extends end date to June 30, 2025","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["First Amendment revises merger consideration: Initial Stock Consideration based on $16.5M less adjustments at $5.7528/share.","Delayed Stock Consideration set at $6.5M less liabilities and working capital deficits, divided by share value and fully diluted shares.","Cash Consideration base $12M, with credits for $5M exclusivity, $300K extension, $695K advances, loaned amount, and working capital adjustment.","End Date extended to June 30, 2025; closing condition requires TuHURA to receive at least $20M from concurrent investment.","CSO Dennis Yamashita terminated Dec 16, 2024; severance $145,833 over 5 months, COBRA 6 months, options vest on 65,597 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154872,"accession_number":"0000950170-25-065860","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K/A","filed_at":"2025-05-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"TuHURA Biosciences appoints Dr. Craig Tendler to board's Nominating and Corporate Governance Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board appointed Dr. Craig Tendler to the Nominating and Corporate Governance Committee effective May 5, 2025.","Dr. Tendler was originally appointed to the Board on March 10, 2025, as previously reported.","This amendment solely updates committee assignment; no other changes from initial 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154873,"accession_number":"0001193125-25-069706","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TuHURA reports FY2024 R&D $13.3M, cash through late Q4 2025; Phase 3 trial to start Q2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2024 R&D expense $13.3M (up from $9.4M); G&A $4.3M (vs $4.1M prior year).","Raised $36M in 2024; cash expected to fund operations through late Q4 2025.","Phase 3 IFx-2.0 trial for MCC under SPA with FDA; enrollment targeted Q2 2025 (partial clinical hold on CMC).","Acquisition of Kineta's VISTA antibody KVA12123 targeted to close Q2 2025.","2025 milestones include Phase 2 VISTA trial in AML; novel bi-specific ADC platform advancing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173386,"accession_number":"0000950170-25-040770","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"TuHURA furnishes investor presentation; merger with Kineta ongoing","summary_kind":"llm","event_type":"m_and_a","confidence":"low","bullets":["Investor presentation used for meetings with investors and analysts starting March 18, 2025.","Presentation discusses proposed merger with Kineta, Inc., but no new deal terms are disclosed.","No new financial or operational data beyond prior SEC filings; content is summary forward-looking information.","Merger completion subject to conditions, including stockholder approvals and financing; risks outlined."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173385,"accession_number":"0000950170-25-037600","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"TuHURA appoints Dr. Craig Tendler (ex-J&J oncology VP) to Board, effective March 10, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Tendler oversaw 30 major oncology drug approvals at J&J, including DARZALEX, ZYTIGA, and BALVERSA.","Received option to purchase 151,883 shares of HURA common stock at closing price on grant date.","TuHURA plans to begin Phase 3 trial of IFx-2.0 in Q2 2025; Tendler's experience expected to aid regulatory strategy.","Board expanded from five to six members with this appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173384,"accession_number":"0000950170-25-021395","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"TuHURA receives $3.0M in secured notes from warrant holders for 1.03M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aggregate $3,011,372.60 in secured promissory notes from four Makers, including KP Biotech Group, CA Patel F&F, Kiran C. Patel, and Donald Wojnowski.","Notes bear 12% simple interest (18% upon default); all principal and interest due by May 30, 2025.","Company issued 1,034,836 restricted common shares upon exercise of warrants; notes secured by those shares.","Makers include company insiders and affiliates; notes represent payment of warrant exercise price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173383,"accession_number":"0000950170-25-001330","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"TuHURA dismisses Marcum as auditor, appoints Cherry Bekaert after merger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum dismissed as independent auditor effective Dec 31, 2024; Audit Committee approved Dec 27, 2024.","No disagreements or reportable events with Marcum in past two fiscal years; going concern note in prior reports.","Cherry Bekaert appointed as new auditor for fiscal year ending Dec 31, 2024, effective Dec 27, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190391,"accession_number":"0001193125-24-276426","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"TuHURA to acquire Kineta in stock/cash merger; $35M concurrent financing required","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Consideration per Kineta share: initial stock based on $15M pool, delayed stock based on $5M, plus cash and contingent asset payment rights.","Closing requires TuHURA to raise at least $35M net proceeds from a concurrent private investment.","TuHURA will loan Kineta up to $900k at 5% interest to fund R&D expenses, secured by program assets.","Key conditions: stockholder approvals (Kineta merger vote; TuHURA authorized share increase to 200M), listing, and no law/order preventing deal.","Termination fee of $1M payable by Kineta if it accepts a superior proposal; $1M by TuHURA if it fails to close the concurrent investment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190390,"accession_number":"0000950170-24-130436","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"TuHURA plans IFx-2.0 Phase 3 trial under SPA; signs non-binding LOI to acquire Kineta's KVA12123","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IFx-2.0 Phase 3 accelerated approval trial in first-line MCC to start H1 2025 under FDA SPA, with ORR primary and PFS secondary endpoints.","Non-binding LOI with Kineta to acquire KVA12123 VISTA antibody via merger; definitive agreement targeted Q4 2024.","Cash runway expected to fund operations late into H2 2025; $31M from Kintara merger plus $5M for Kineta exclusivity.","Hired Peter O'Neill as VP Clinical Operations and Michael Krsulich as Head of Quality Assurance.","REM-001 photodynamic therapy study for cutaneous metastatic breast cancer enrollment expected to complete Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190389,"accession_number":"0000950170-24-127673","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"TuHURA raises CEO & CFO base salaries; grants options for 1.56M shares at $4.94","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Bianco base salary increased to $499,000; CFO Dearborn to $375,000, effective Jan 1, 2025.","Bianco granted options for 1,065,990 shares; Dearborn for 489,848 shares, exercise price $4.94.","Options vest in 1/3 annual installments over 3 years, 10-year term, under 2024 Equity Incentive Plan.","Compensation Committee set salaries at ~80% of peer group 50th percentile.","Approved form of stock option agreement, filed as Exhibit 10.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190388,"accession_number":"0000950170-24-127218","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K/A","filed_at":"2024-11-14T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"TuHURA posts $15.7M net loss through Q3 2024; convertible debt rises to $24.4M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $15.7M for nine months ended Sep 30, 2024 vs $26.6M prior year (prior year included $16.2M IPR&D charge).","Operating loss of $12.0M vs $27.1M YoY; R&D spend up to $9.4M from $7.5M.","Cash position $19.6M at Sep 30, 2024, up from $3.7M year-end 2023 after $28.6M convertible note issuance.","Convertible notes payable net of discount total $24.4M; derivative liability of $2.9M recorded.","Stockholders' deficit worsened to $(2.8M) from $(1.6M); closed merger with Kintara on Oct 18, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190387,"accession_number":"0000950170-24-115765","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2024-10-21T23:59:59+00:00","items":["2.01","1.01","9.01","5.02","2.02","3.03","5.01","5.03","5.06","8.01"],"status":"ready","headline":"Kintara completes reverse merger with TuHURA; renamed TuHURA Biosciences, trades as HURA","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger closed Oct 18, 2024; Kintara securityholders own ~2.85% of combined entity (or 5.45% if CVR milestone met).","TuHURA securityholders own ~97.15% (or 94.55% after CVR shares).","1-for-35 reverse stock split pre-merger; common stock now trades under HURA on Nasdaq.","CVRs issued to former Kintara holders; up to ~1.54M shares payable if REM-001 CMBC study milestone met by Dec 31, 2025.","Combined company focuses on TuHURA's personalized cancer vaccine IFx-2.0; Phase 3 trial in MCC planned for Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190386,"accession_number":"0000950170-24-114690","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Kintara retracts Oct 17 CVR record date; CVRs to pre-reverse-split holders ahead of Oct 18 merger","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["CVRs will be issued to stockholders of record immediately prior to the 1-for-35 reverse split, not on Oct 17 as previously announced.","Reverse split and merger with TuHURA expected to close Oct 18, subject to regulatory approval and remaining conditions.","Each CVR entitles holder to aggregate of up to 53,897,125 shares of common stock upon milestone achievement, adjusted for reverse split.","Kintara does not anticipate the correction will change which stockholders receive CVRs or the number received.","Previously approved reverse split range was 1-for-20 to 1-for-40; final ratio set at 1-for-35."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190385,"accession_number":"0000950170-24-114471","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Kintara sets Oct 17 record date for CVRs; TuHURA merger expected Oct 18","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Record date of Oct 17, 2024 for CVR issuance to Kintara stockholders.","Merger with TuHURA Biosciences expected to close Oct 18, subject to conditions.","CVRs entitle holders to aggregate 53,897,125 shares, adjusted for 1-for-35 reverse split.","1-for-35 reverse stock split to be effected immediately prior to merger close.","Each common share receives one CVR; warrants also participate on per-share basis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190384,"accession_number":"0000950170-24-113526","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2024-10-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"TuHURA reports H1 2024 net loss $10.1M, cash $12.3M; merger with Kintara on track for Q4 2024","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Net loss $10.1M for six months ended June 30, 2024; prior period loss $22.1M incl $16.2M IPR&D charge.","Cash $12.3M as of June 30, 2024, up from $3.7M at Dec 31, 2023; R&D expense $6.4M vs $4.0M YoY.","Convertible notes payable net $16.2M; derivative liability $2.0M; accumulated deficit $98.6M.","All-stock merger with Kintara expected to close Q4 2024; combined company to trade as HURA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190383,"accession_number":"0000950170-24-113404","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2024-10-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Kintara stockholders approve TuHURA merger; FY2024 net loss $8.32M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Stockholders approved merger with TuHURA on Oct 4, 2024; closing expected mid-October 2024.","Cash and equivalents $4.9M as of June 30, 2024.","FY2024 net loss $8.3M ($0.32 loss per share), improved from $14.6M ($9.27 loss) in FY2023.","REM-001 study dosed 4 patients; $2.0M NIH grant covers most costs; R&D expenses fell 71%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190382,"accession_number":"0000950170-24-112899","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Kintara shareholders approve merger proposals; charter increase and reincorporation fail","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq Proposal to approve merger share issuance passed: 26.75M for, 1.18M against.","Reverse stock split (1:20-1:40) approved; Charter increase to 400M shares failed.","Reincorporation to Delaware failed; TuHURA 2024 Equity Plan and Golden Parachute approved.","Merger with TuHURA expected to close in mid-October 2024, pending remaining conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206896,"accession_number":"0000950170-24-109377","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2024-09-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Kintara and TuHURA waive two stockholder approval conditions for merger; reverse split condition added","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["TuHURA waives requirement for Kintara stockholder vote on reincorporation from Nevada to Delaware.","Authorized share increase vote waived conditional on Kintara effecting a reverse stock split of 1-for-35 or greater.","Waiver Agreement dated September 25, 2024, does not alter other Merger Agreement terms.","Kintara previously filed a definitive proxy/prospectus for the merger (S-4 effective August 13, 2024)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206895,"accession_number":"0000950170-24-108892","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2024-09-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kintara adjourns special meeting; merger vote faces shortfall, adjourned to Oct 4","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting adjourned to Oct 4, 2024 at 9:00 am EST; voting threshold not reached for Proposals 3 & 5.","ISS and Glass Lewis recommend stockholders vote FOR both proposals to permit merger with TuHURA.","Voting deadline is Oct 3 at 11:59 pm EST; all eligible stockholders urged to vote.","If merger not completed, Kintara warns its future is uncertain; shares may be at risk."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206894,"accession_number":"0000950170-24-108415","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Kintara adjourns special meeting to Oct 4 due to insufficient votes on merger-related proposals","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special Meeting on Sept 20, 2024 adjourned to Oct 4, 2024 because insufficient votes on Proposal 3 (increase authorized shares to 400M) and Proposal 5 (reincorporation to Delaware).","Only the adjournment proposal was voted on and approved (24,945,610 for, 6,079,445 against, 587,527 abstain).","The merger with TuHURA Biosciences is conditioned on approval of these proposals.","Stockholders who already voted do not need to revote; proxies remain valid."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206893,"accession_number":"0000950170-24-107916","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2024-09-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kintara and TuHURA post on social media urging vote on merger at Special Meeting","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Posts on LinkedIn and X on Sep 18, 2024, regarding Kintara's Special Meeting for the proposed merger with TuHURA.","Stockholders are urged to vote in favor of the merger; proxy statement/prospectus effective Aug 13, 2024.","No new financial terms disclosed; this is a solicitation communication under Rule 425.","The merger is subject to stockholder approval; closing conditions remain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206892,"accession_number":"0000950170-24-107609","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2024-09-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kintara says merger vote threshold not yet met; stockholders urged to vote by Sept 19","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Special meeting on Sept 20; votes must be cast by 11:59pm ET Sept 19 to count.","Proposals 3 & 5 require majority of outstanding shares as of Aug 14, 2024 to be voted FOR.","ISS and Glass Lewis both recommend stockholders vote FOR Proposals 3 & 5.","CEO warns if merger not completed, Kintara's future is uncertain; $31M financing backs deal.","Preliminary tabulation shows voting threshold not reached on Proposals 3 & 5."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206891,"accession_number":"0000950170-24-105344","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Kintara sets Sept 20 vote on TuHURA merger; REM-001 enrolled 4 of 10 patients; warns of bankruptcy without deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special Meeting on Sept 20, 2024 to vote on TuHURA merger; existing holders get 5.45% of combined co. plus CVRs.","REM-001 CMBC study: 4 of 10 target patients enrolled as of Sept 10, 2024; no safety issues; Phase 3 dose assessment ongoing.","Without the merger, Kintara states it likely lacks adequate resources to continue operations and may seek bankruptcy protection.","Majority of REM-001 costs covered by $2.0M SBIR grant from NIH; potential to offer much needed treatment for CMBC.","CVRs allow additional shares if ≥10 patients enrolled and complete 8-week follow-up by Dec 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206890,"accession_number":"0000950170-24-104739","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kintara warns of possible bankruptcy if TuHURA merger fails; special meeting Sept 20","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Special meeting to approve merger with TuHURA set for Sept 20, 2024; vote deadline Sept 19 at 11:59 p.m. ET.","Kintara warns that if merger fails, it may lack capital to continue and could seek bankruptcy protection.","Under merger terms, Kintara equityholders to own ~2.85% (or ~5.45% with CVR) of combined company; TuHURA holders ~97.15%.","Combined company expected to trade on Nasdaq as \"HURA\"; closing expected in Q3 2024.","Board recommends voting FOR all proposals, including charter amendment and reincorporation to Delaware."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206889,"accession_number":"0000950170-24-102932","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kintara warns stockholder vote failure could lead to bankruptcy, delisting","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Voting deadline for merger with TuHURA is Sept 19, 2024 at 11:59 p.m. ET; special meeting Sept 20.","If Proposals 3 & 5 don't get majority support, merger cannot close; company may lack capital and seek bankruptcy.","Without approval, common stock likely delisted from Nasdaq Capital Market.","Upon merger close, each share/warrant gets one contingent value right (CVR) tied to REM-001 program milestone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206888,"accession_number":"0000950170-24-098289","cik":1498382,"company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","form_type":"8-K","filed_at":"2024-08-19T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Kineta reopens VISTA-101 trial; 30 of 39 patients enrolled; KVA12123 safe","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Kineta reopened enrollment in VISTA-101 Phase 1/2 trial for KVA12123; expects full enrollment by end of 2024.","30 of projected 39 patients enrolled; cleared 5th of 6 monotherapy dose levels and 2 of 4 combination cohorts.","Initial results showed partial response and stable disease in combo cohorts; durable stable disease in monotherapy.","KVA12123 demonstrated no dose-limiting toxicities and no CRS-associated cytokines at any dose level.","TuHURA has exclusive right to negotiate acquisition until Oct 1, 2024 (extendable) after $5M nonrefundable payment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":150290767.4285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-08-19T23:59:59+00:00|206888"}